Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Strongbridge Bio Ord (NQ: SBBP)
5.230 USD  +0.130 (+2.55%)
Official Closing Price  /  Updated: 4:11 PM EST, Nov 21, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 169,600
Open 5.120
Bid (Size) 3.600 (169)
Ask (Size) 6.160 (1)
Prev. Close 5.100
Today's Range 5.100 - 5.350
52wk Range 3.850 - 9.250
Shares Outstanding 35,335,026
Dividend Yield N/A
Performance
YTD
-30.73%
-30.73%
1 Month
+10.11%
+10.11%
3 Month
-3.15%
-3.15%
6 Month
-30.27%
-30.27%
1 Year
-17.64%
-17.64%
Top News
More News
Strongbridge Biopharma plc Announces Presentation of New Data Comparing the In Vitro Effects of Levoketoconazole, the Active Ingredient in RECORLEV™, and Ketoconazole on Human Cortisol Production
Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet... Read More
from GlobeNewswire News Releases
Strongbridge Biopharma plc to Present at the Stifel 2018 Healthcare Conference
Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet... Read More
from GlobeNewswire News Releases
More News
Read More
Positive Developments for Treating Patients With Recurrent Malignant Tumors Significant for Novel Therapeutic Strategies
from PR Newswire
Positive Developments for Treating Patients With Recurrent Malignant Tumors Significant for Novel Therapeutic Strategies
category Featured News
from FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Strongbridge Biopharma plc Reports Third Quarter 2018 Financial Results and Provides Corporate Update
from GlobeNewswire News Releases
Strongbridge Biopharma plc Enters into Agreement for Novo Nordisk to Acquire the U.S. and Canadian Rights to MACRILEN™ (macimorelin)
from GlobeNewswire News Releases
Strongbridge Biopharma plc Presents Detailed Initial Results from Pivotal Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome at the 18th Annual Con
from GlobeNewswire News Releases
Detailed Research: Economic Perspectives on MTS, Delek US, Alarm, Strongbridge Biopharma, Myriad Genetics, and Matson — What Drives Growth in Today's Competitive Landscape
from GlobeNewswire News Releases
Peek Under The Hood: SPTM Has 17% Upside
category ETFs
from ETF Channel
Strongbridge Biopharma plc to Participate in Two Upcoming Healthcare Investor Conferences
from GlobeNewswire News Releases
10 Hottest Stocks From October 31, 2018
category TNXP , SBBP , Benzinga , and 16 more.
from Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.